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Hemodynamic effects of prostaglandin E, 
infusion in patients with acute myocardial 
infarction and left ventricular failure 
Prostaglandin E, (PGE,) has been shown to limit infarct size, improve coronary blood flow, inhibit 
platelet aggregation, and reduce both left ventricular (LV) preload and afterload in experimental 
animals. Its use in the therapy of patients with acute myocardial infarction (AMI) and congestive 
heart failure (CHF) has not, however, been reported. Five patients with ABM of less than 12 hours’ 
duration and LV dysfunction were studied to assess the hemodynamic effects of IV infusion of 
PGE,. PGE, in the concentration of 0.4 rg/ml was infused at a rate of 0.003 pg/kg/min (3 
ng . kg-’ . min-I) to a maximum rate of 0.021 Fg/kg/min (21 ng . kg-’ . min-‘) for a total time of 
up to 90 minutes. There was an insignificant increase in heart rate, with significant decreases in 
mean arterial blood pressure and systemic vascular resistance. Pulmonary capillary wedge 
pressure declined from 21 i 3 to 15 i 1 mm Hg (p < O.OS), mean pulmonary artery pressure and 
pulmonary vascular resistance decreased (p < 0.05), with increases in cardiac index from 
2.38 ? 0.08 to 2.89 + 0.58 L/min/m’ (p < 0.01) and stroke volume from 51 + 17 to 59 + 20 
ml/beat (p < 0.05). No major cardiac or extracardiac side effects were encountered during PGE, 
infusion. One patient had transient nausea which did not require discontinuation of the drug. 
PGE, is an effective vasodilator and deserves further application in therapy for AMI patients with 
CHF. (AM HEART J 103:485, 1982.) 
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Prostaglandin E, (PGE,) has been shown to improve 
coronary blood Aow,‘-~ reduce both left ventricular 
(LV) preload and afterload,2-5 decrease platelet 
aggregationP and limit infarct size in anima1s.7*8 
Recent animal studies have shown that PGE, signif- 
icantly reduces cardiac work and diminishes ST 
segement elevation during myocardial ischemia.s Its 
use in therapy for patients with acute myocardial 
infarction (AMI) and LV dysfunction has not, how- 
ever, been reported. In part, the lack of PGE, 
application in clinical AM1 appears to be the result 
of concern about gastrointestinal or other distress- 
ing side effects. The purpose of the present patient 
study was to determine whether administration of 
PGE, could beneficially alter the hemodynamic 
disturbances associated with AM1 without adverse 
side effects. 
METHODS 
Patient population. Five patients, including three men 
and two women ages 46 to 72 years (mean age, 64 years), 
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with AM1 of less than 12 hours’ duration and LV dysfunc- 
tion, were studied. LV dysfunction was defined by the 
presence of bibasilar pulmonary rales and/or third heart 
sound and LV filling pressure (LVFP) of more than 15 
mm Hg. Four patients had ECG evidence of anterior and 
one of inferior transmural AMI. The diagnosis of transmu- 
ral infarction was based on ECG findings of acute ST 
segment elevation followed by development of pathologic 
Q waves or substantial decrease in R wave voltage, 
coincident with serum myocardial enzyme changes typical 
of AMI. Three patients were in Killip class II and two 
patients were in Killip class IIL’O Conventional treatment, 
including sedation, oxygen, narcotics, and antiarrhythmic 
agents such as lidocaine, was prescribed when indicated 
but the administration of any vasodilators, diuretics, or 
other agents with known substantive hemodynamic 
effects was withheld until hemodynamic study of PGE, 
had been completed. 
Hemodynamic determinatlons. The patients were 
admitted to the coronary care unit and informed consent 
was obtained. A 7F Lexington thermodilution catheter 
was positioned in the pulmonary artery (PA) via an 
antecubital vein cutdown and a short plastic catheter was 
inserted percutaneously into the radial artery. PA pres- 
sure and systemic arterial pressure (AP) were monitored 
simultaneously by use of Statham P231D and Bently 800 
transducers, respectively. Cardiac output (CO) was mea- 
sured by the thermodilution technique with the use of 10 
ml of sterile normal saline at room temperature. Each CO 
recorded was the mean of at least two consecutive deter- 
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Table I. Peak hemodynamic responses during PGE, infusion in AM1 
HR MAP PCW MPAP CI sv SVR PVR P.4R 
(bpm) (mm Hg) (mm Hg) (mm Hg) (Llminlm’) (ml) (dyne set cm-‘) (dyne set cm’) (dyne see cmj) 
Control 78 -+ 18 101 of- 8 21 + 3 27 t 4 2.38 of; 0.08 51 i 17 1710 t 527 509 zt 124 123 zk 52 
PGE, 83 i 18 92 f  5 15 rt 1 21 + 3 ‘2.89 k 0.58 59 r 20 1373 + 423 323 + 80 89 t 44 
p Value NS < 0.05 < 0.05 < 0.05 < 0.01 < 0.05 < 0.05 < 0.01 < 0.01 
Values expressed as mean + SEM. PCW = pulmonary capillary wedge pressure; MPAP = mean pulmonary artery pressure; PVR = pulmonary vascular 
resistance: NS = not significant (p > 0.05). 
mmations having the maximal variation of less than 10 ‘% .
The ECG lead with the greatest ST segment elevation was 
monitored. Blood was drawn for routine hematologic and 
blood chemistry studies before and during the PGE, 
infusion. Control hemodynamic indices including heart 
rate (HR), phasic and mean systemic AP, LVFP measured 
as pulmonary capillary wedge pressure, phasic and mean 
PA pressure, and CO were determined at least twice at 
15-minute intervals before the infusion. 
PGE, infusion. A solution of PGE, (Prestin VR, Upjohn 
Co., Kalamazoo, Mich.) containing 0.4 fig/ml was prepared 
with 5 % dextrose. PGE, infusion, regulated by a Harvard 
pump (Model 901), was begun in the central venous 
circulation and the dose was slowly increased every 10 to 
15 minutes. Intravenous infusion was increased to 1 to 70 
ml/min at 10 minutes and to 3.50 ml/min at 20 to 30 
minutes. The desirable hemodynamic effects were 
achieved at dosage range of 10 to 19 ng . kg-l . min-‘, with 
the average effective dose of 14.6 ng . kg-’ . min-‘. The 
infusion rate was modified if systolic AP fell by 20 mm Hg 
or more, if HR increased more than 20 bpm, or if LVFP 
fell below 15 mm Hg. Hemodynamic measurements were 
recorded every I5 minutes for the total infusion time of 90 
minutes and for a further 60 minutes after the infusion 
had been discontinued. 
Hemodynemic-related indices calcdated. The follow- 
ing indices were derived: SW1 = SVI X (MSP - LVFP) X 
1.36/100, where SW1 represents stroke work index 
(gm . m/m2), SVI is stroke volume index (ml/m*), and 
MSP is mean systemic pressure (mm Hg). SVR = K 
(mean aortic pressure)/systemic flow = 80 @@/CO, and 
PVR = K (mean pulmonary pressure)/pulmonary 
flow = 80 (m)/CO, where SVR represents systemic vas- 
cular resistance, PVR is total pulmonary vascular resis- 
tance, m is mean aortic pressure, and i% is mean 
pulmonary pressure; K represents the conversion factor 
from hybrid unite of mm Hg . L-’ . min-’ to metric units 
of dyne . set . cmm5. PAR = (PA - LVFP x SO)/CO, 
where PAR is pulmonary arteriolar resistance. 
Statistical analysis. Statistical analysis was performed 
by use of Student’s paired t test. Numerical values are 
reported as mean 2 SEM. 
RESULTS 
Hemodynamic effects. The results of control and 
peak hemodynamic responses during the PGE, infu- 
sion are shown in Table I. During PGE, infusion, 
HR increased slightly but did not reach statistical 
significance. However, there were significant 
decreases in mean systemic arterial pressure (MAP) 
and mean pulmonary pressure (MPP) (Fig. 1). In 
addition, LVFP, SVR, PVR, and PAR were signifi- 
cantly reduced by PCE, (Figs. 2 and 3), while stroke 
volume (SW, cardiac index (CD, and SW1 were 
increased (Figs. 2 and.4). Following d&continuation 
of PGE, infusion, all hemodynamic parameters in 
four of the five patients returned to control values 
within 30 to 60 minutes. At this point, patients were 
treated with conventional vasodilators. In one 
patient, the pulmonary capillary wedge pressure 
remained normal for up to 2 hours. 
Anti-lschemic eftects.Three patients had complete 
relief of their chest pain during PGE, infusion. 
There were, however, no significant ST changes in 
the monitored precordial lead. 
Side effects. No major side effects were encoun- 
tered during the PGE, infusion; in particular there 
was no abdominal discomfort, vomiting or diarrhea. 
However, it should be pointed out that this was a 
pilot study with only a short duration of infusion. 
One patient had transient nausea but did not feel 
this sufficient to discontinue study. 
DISCUSSION 
Beneficial hemodynamk effects of POE, in AMI with 
congestive heart failure (CHF) due to balanced sy8temic 
arteriovenous dilation. The present study demon- 
strates that administration of PGE, to patients with 
AM1 complicated by CHF results in significant 
hemodynamic improvement and relief of LV dys- 
function without significant tachycardia or other 
side effects. The lack of substantive untoward extra- 
cardiac events such as nausea, vomiting, and diar- 
rhea despite hemodynamic improvement may be 
related to the relatively small doses of PGE, neces- 
sary to reduce LVFP and SVR, thereby relieving 
pulmonary congestion and improving pump output. 
Although previous animal studies have not sug- 
gested an effect of PGE, on venous capacitance, the 
results of the present study demonstrate reduction 
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C * p value < 0.05 6 
Fig. 1. Control (C) and peak (P) values of heart rate 
(H-Rate), MAP, and MPP in response to PGE, infusion. 
PNT = patient. 
of LVFP to normal with moderate decrease in SVR 
accompanied by only modest rises in SV and CI. 
Thus, the considerable reduction in LVFP suggests 
that in AM1 patients with CHF, PGE, therapy 
results in systemic venorelaxation. 
Potential anti-ischemic properties of PGE,. Although 
the present study was designed to examine the acute 
hemodynamic actions of PGE1, this agent is also 
known to have other effects that may be of benefit in 
myocardial ischemia. PGE, has been shown to pre- 
serve myocardial cells during ischemia and diminish 
autolytic processes as evidenced by decreased myo- 
cardial creatine kinase (CK) and cathepsin D release 
and by preservation of myocardial CK activity, 
indicating protection of cardiac cell integrity.7**1 
PGE, increases coronary blood flow and decreases 
coronary vascular resistance.‘, l2 PGE, also protects 
against isoproterenol-induced myocardial injury as 
evidenced by significant reductions in ST segment 
elevation and plasma free fatty acid concentration.13 
In addition, PGEI, inhibits norepinephrine releaseI 
and the attendant increase in lipolysis, thereby 
limiting the deleterious myocardial oxygen wasting 
effect resulting from catecholamine rise during AMI. 
The coronary vasodilatory action of PGE, in con- 
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Fig. 2. Control (C) and peak (P) values of SVR, pulmo- 
nary capillary wedge pressure (PCW), PVR, and CI in 
response to PGE, infusion. 
junction with reduced LV preload might favorably 
redistribute myocardial perfusion toward the suben- 
docardium, the area most critically compromised 
during acute ischemia. It is also possible that PGE, 
might increase collateral blood flow directly or by 
reducing LVFP. Of particular interest is PGE, inhi- 
bition of platelet aggregation,15 since recent studies 
have indicated increased platelet aggregation in 
AM1 patients and a pathogenetic role of such plate- 
let dysfunction in the infarction process.‘“-‘* 
Potential advantages of PGE, compared to other 
vasodllators in AM. The beneficial hemodynamic 
effects observed in the present study have also been 
observed with other vasodilators such as nitroprus- 
side and nitroglycerin. ls, 2o However, the use of nitro- 
prusside in the presence of acute myocardial ische- 
mia has been of concern to some workers, since 
animal studies have suggested that nitroprusside 
may adversely alter the distribution of myocardial 
blood flow during experimental infarction.21s22 
Hence, an alternative means of acute afterload 
reduction appears useful. While not directly com- 
pared, the effects of PGE, in this study seem similar 
to the balanced systemic arterial and venous dila- 
tion caused by nitroprusside, as shown by the 16% 
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Fig. 3. Control (C) and peak (P) response values of PAR 
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Fig. 4. Effects of PGE, infusion on left ventricular func- 
tion measured as the relation between changes in SW1 and 
LVFP. 
increase in SV and 29% reduction in LVFP pro- 
duced by PGE,. Nitroglycerin exerts a beneficial 
hemodynamic effect in AM1 patients without 
increasing ST segment elevation or adversely affect- 
ing distribution of myocardial perfusion.20 However, 
nitroglycerin does not possess some of the other 
potential salutary properties of PGE, such as inhibi- 
tion of catecholamine release and diminished plate- 
let aggregation. While another prostagl&ndin, pros- 
tacyclin (PGI,), provides greater in vitro anti&&&t 
aggregation and more potent coronary vasodilation 
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compared to PGE,, the use of PGI, in AM1 patients 
with congestive heart failure appears limited due to 
marked PGI,-induced systemic vasodilation and 
hypotension. 
Conclusions. Although the number of patients 
included in the present study was relatively small, 
the salutary hemodynamic results are significant. In 
view of our clinical observations and the experimen- 
tal data of others suggesting additional beneficial 
actions of PGE1, this therapeutic agent deserves 
further evaluation in the management of patients 
with AM1 and LV failure. 
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Comparative hemodynamic effects of digoxin vs 
nitroprusslde in conscious dogs with aortocaval 
fistula-induced chronic left ventricular volume 
overload and normal systolic performance 
We compared the effects of IV digoxin (0.04 mg/kg) and nitroprusside (MP) (1.2 and 1.8 
I.cg/kg/min) on left ventricular (i.V) performance in six preinstrumented conscious dogs with 
chronic volume overload and congestive heart failure (CHF) produced by an aortocavai fist&a. At 
3 and 8 hours after digoxin administration (serum level, 3.5 -c 0.6 ng/mi), there were no changes 
in heart rate, LV systolic (LVSP) and end-diastolic (LVEDP) pressures, LV dimensions, LV dP/dh,,, 
or percent minor diameter shortening as compared to control values in the resting state, after 
beta blockade, or during phenyiephrine infusion. By contrast, NP produced a significant 
reduction (p < 0.05) in LVEDP (16 1?: 3 to 10 2 3 mmHg) at the smaller dose which caused no 
change in mean aortic pressure. The larger dose of NP further reduced LVEDP and evoked 
significant (p < 0.05) decreases in LVSP .(124 + 5 to 117 + 7 mm Hg), mean aortic pressure 
(85 2 3 to 78 r 5 mm Hg), and LV end-diastolic dimension (LVEDD) (53.0 + 5.5 to 52.0 + 5.7 
mm), while augmenting LV dP/dt,,,,, (3288 f  266 to 3647 f  130 mm Hg/sec). Beta blockade with 
IV propranolol (2.0 mg/kg) prevented the rise in LV dP/dt,,, after high-dose NP administration 
but did not alter the reductions in mean aortic pressure, LVEDP, and LVEDD. This study indicates 
that NP, but not digitalis, has a favorable effect on LV hemodynamics in the volume-overloaded 
heart with normal LV systolic contraction and high-output CHF resulting from increased blood 
volume and reduced LV diastolic compliance. At least part of the apparent improvement in LV 
performance observed with high-dose NP is sympathetically mediated since it can be attenuated 
by beta blockade. (AM HEART J 103:489, 1982.) 
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Antonio, Texas 
The digitalis glycosides have been used to treat 
patients with congestive heart failure (CHF) for 
almost 200 years.’ However, there is still consider- 
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able controversy concerning the short- and long- 
term salutary effects of digitalis on left ventricular 
(LV) performance in the normal and the failing 
heart. While most experimental animal and patient 
studies have demonstrated an enhancement of LV 
performance by digitalis?-” other studies have 
demonstrated minor or variable improvement.18-22 
The effects of the cardiac glycosides on LV perfor- 
mance may vary depending on the pretreatment 
inotropic state, the peripheral vascular resistance, 
the route of administration, the level of circulating 
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